Clinical Trials
109 trialsNIVOTHYM
European Organisation for Research and Treatment of Cancer - EORTC
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
ADEPPT
ETOP IBCSG Partners Foundation
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
SWOG Cancer Research Network
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Canadian Cancer Trials Group
ICARS
European Organisation for Research and Treatment of Cancer - EORTC
Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer
Canadian Cancer Trials Group
CHESS
ETOP IBCSG Partners Foundation
BOOSTER
ETOP IBCSG Partners Foundation
RAISE
ETOP IBCSG Partners Foundation
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
AMAZE-lung
ETOP IBCSG Partners Foundation
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC
European Organisation for Research and Treatment of Cancer - EORTC
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
NEMO
European Organisation for Research and Treatment of Cancer - EORTC
reICB
EuroCityClinic LLC
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
SOURCE Lung
Cancer Trials Ireland
ALERT-lung
ETOP IBCSG Partners Foundation
POSTILV
Radiation Therapy Oncology Group
AMBER
ETOP IBCSG Partners Foundation
STIMULI
ETOP IBCSG Partners Foundation
ALKALINE
European Organisation for Research and Treatment of Cancer - EORTC
BOUNCE
ETOP IBCSG Partners Foundation
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
SWOG Cancer Research Network
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
SWOG Cancer Research Network
STEREO
ETOP IBCSG Partners Foundation
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
Canadian Cancer Trials Group
REACTION
European Organisation for Research and Treatment of Cancer - EORTC
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
Canadian Cancer Trials Group
Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
Eastern Cooperative Oncology Group
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Eastern Cooperative Oncology Group
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Eastern Cooperative Oncology Group
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
Eastern Cooperative Oncology Group
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
Eastern Cooperative Oncology Group
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
Eastern Cooperative Oncology Group
Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer
Eastern Cooperative Oncology Group
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Eastern Cooperative Oncology Group
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
European Organisation for Research and Treatment of Cancer - EORTC